4LIVING Biotech
Clinical-stage biotech developing a CXCR4-targeted ARDS therapy and a companion diagnostic for critically ill patients
Highlights
- New on EvolcAdded 2026-11-11
About 4LIVING Biotech
4LIVING Biotech (4LB) is a clinical-stage biotechnology company focused on Acute Respiratory Distress Syndrome (ARDS). Its precision medicine program pairs 4P021, a CXCR4-targeted therapy, with CX-DiagPlex, a rapid biomarker-based point-of-care test intended to identify eligible patients at ICU admission.
The company works within a translational research framework originally developed by 4P-Pharma, a French start-up studio, and collaborates with key opinion leaders and clinical partners including the University Hospitals of Bordeaux, Tours and Lille. The CHOPIN study, co-sponsored with CHU Bordeaux, is validating the patient stratification approach, and a Phase 2a/2b biomarker-guided trial is planned.
4LB was incorporated in mid-2020 as a subsidiary of 4P-Pharma and is headquartered in Lille, France. The company holds an EU Orphan Drug Designation for ARDS (EU/3/24/2899) and obtained Clinical Trial Authorizations for its LEONARDO study in five European countries. An IQVIA market analysis cited on the website estimates about 564,000 ARDS cases in the EU5 and about 697,000 in the US.
Product: 4P021, a CXCR4-targeted therapy for ARDS in clinical development, and CX-DiagPlex, a rapid biomarker-based companion diagnostic.
Jobs at 4LIVING Biotech
More biotech & pharma companies
4MOVING Biotech
Clinical-stage biotech developing intra-articular GLP-1 therapy 4P004 for knee osteoarthritis patientsNew on Evolc4P-Pharma
Clinical-stage biotech developing drug candidates for serious diseases with unmet medical needsAb Science
Develops pharmaceutical compounds for clinical programs in neurology, inflammatory diseases, oncology and viral diseasesAbbelight
Bioimaging platform, reagents and software for life-science researchers doing 3D super-resolution microscopyAbcely
Develops oral sIgA immunotherapies for mucosal cancers and other mucosal diseasesYoung companyNew on EvolcAbivax
Develops obefazimod and other therapeutics for patients with chronic inflammatory diseases
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.